First of Its Kind AI Technology Analyzes Fast-Growing Brain Tumors on MRI

By MedImaging International staff writers
Posted on 12 Oct 2022

Image: Neosoma HGG is the first AI-based neuro-oncology software to receive (FDA) 510(k) clearance (Photo courtesy of Neosoma)

High-Grade Gliomas, which includes Glioblastoma, are the most common, and most challenging, malignant primary brain cancers. In clinical practice, the brain MRI is the physician’s best tool to evaluate the details and changes in a brain tumor. However, even for the most experienced physicians this presents considerable challenges, which can have a direct impact on clinical care. Now, an advanced AI-based technology produces precise and accurate brain tumor analysis on brain MRIs, providing physicians with critical insights to help them deliver optimal treatment.

Neosoma HGG (High-Grade Glioma) from Neosoma, Inc. (Groton, MA, USA) is the first technology of its kind to support neuro-oncology clinicians in improving treatment of brain cancers. Neosoma HGG conducts detailed tumor segmentation, volumetric measurements, generates imaging for 3D geometric analysis and longitudinally tracks patients with high-grade glioma brain tumors. These features will help physicians to better plan procedures, assess post-procedural results, guide chemo and immunotherapy treatments and support an improved patient experience. Neosoma HGG is combined with the proprietary Neosoma Clinical Management Software Platform, allowing the multi-disciplinary physician team more effectively centralize clinical data, plan and track patient care, and significantly increase efficiency.

The Neosoma HGG AI-based neuro-oncology software device has received U.S. Food and Drug Administration (FDA) 510(k) clearance. Performance testing results, submitted to the FDA demonstrated that Neosoma HGG’s outputs exceeded that of individual neuro-radiology experts. When compared to a consensus of neuroradiologists, Neosoma HGG achieved an excellent 95.5% accuracy in measuring tumor volumes at multiple timepoints of patient care.

“Clinicians commonly debate the results of brain MRIs and whether the brain tumor is stable, responding to treatment, or progressing. Neosoma HGG will give us the objectivity needed to make our decisions easier and more accurate,” commented Isabelle M. Germano, MD, MBA, FACS, Professor of Neurosurgery and Director of the Comprehensive Brain Tumor Program at The Mount Sinai Medical Center.

“Neosoma HGG will give us a novel tool allowing for comprehensive longitudinal monitoring and understanding of brain tumors, assist in our decision making, and will be a valuable part of our clinical practice. I look forward to using this new and important technology,” stated Roger Stupp, M.D., Chief of Neuro-oncology and Co-director of the Northwestern Medicine Malnati Brain Tumor Institute and Professor of Neurological Surgery, Neurology and Medicine at Northwestern University.

Related Links:
Neosoma, Inc.